Ian Kerridge

Ian Kerridge

Auto-generated profile, based on publicly available information

Ian Kerridge

The University of Sydney, Sydney, Australia

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2015 in Psycho-Oncology
Verified
Journal Article
Open access
PDF file
SJStephanie Johnson
Stephanie Johnson
PBPhyllis Butow
Phyllis Butow
IKIan Kerridge
Ian Kerridge
MTMartin Tattersall
Martin Tattersall
Background: Patients with advanced cancer may benefit from end of life (EOL) planning, but there is evidence that their willingness and desire to engage in advance care planning (ACP) varies. The reasons for this remain poorly understood. Previous reviews on ACP most commonly report outcome measures related to medical interventions and type of care. Synthesis of the literature, which aims to illuminate the salient characteristics of ACP and investigates the psychological and social features of preparation for the EOL, is required.Methods: We searched Medline, EMBASE, PsychINFO, CINAHL, and the Cochrane Central Register of Controlled Trials for studies on perceptions or experiences regarding ACP of adults with cancer, family, friends, or professionals caring for this group. Databases were searched from earliest records to 19 November 2014. A thematic analysis of the literature generated conceptual themes.Results: Of the 2483 studies identified, 40 were eligible for inclusion. Studies addressed the relational nature of ACP, fear surrounding ACP, the conceptual complexity of autonomy, and the influence of institutional culture and previous healthcare experiences on ACP.Conclusions: The complex social and emotional environments within which EOL planning is initiated and actioned are not sufficiently embedded within standardized ACP. The notion that ACP is concerned principally with the ‘right’ to self‐determination through control over treatment choices at the EOL may misrepresent the way that ACP actually occurs in cancer care and ultimately conflict with the deeper concerns and needs of patients, who experience ACP as relational, emotional, and social. Copyright © 2015 John Wiley & Sons, Ltd.

20 August 2010 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
BGB. George
B. George
NPN. Pati
N. Pati
NGN. Gilroy
N. Gilroy
MRM. Ratnamohan
M. Ratnamohan
GHG. Huang
G. Huang
KBK. Bradstock
K. Bradstock

29 December 2015 in BMC Public Health
Verified
Journal Article
Open access
PDF file
CDChris Degeling
Chris Degeling
JJJane Johnson
Jane Johnson
IKIan Kerridge
Ian Kerridge
AWAndrew Wilson
Andrew Wilson
MWMichael Ward
Michael Ward
GGGwendolyn Gilbert
Gwendolyn Gilbert
‘One Health’ represents a call for health researchers and practitioners at the human, animal and environmental interfaces to work together to mitigate the risks of emerging and re-emerging infectious diseases (EIDs). A One Health approach emphasizing inter-disciplinary co-operation is increasingly seen as necessary for effective EID control and prevention. There are, however, socio-political, ethical and legal challenges, which must be met by such a One Health approach. Based on the philosophical review and critical analysis of scholarship around the theory and practice of One Health it is clear that EID events are not simply about pathogens jumping species barriers; they are comprised of complex and contingent sets of relations that involve socioeconomic and socio-political drivers and consequences with the latter extending beyond the impact of the disease. Therefore, the effectiveness of policies based on One Health depends on their implementation and alignment with or modification of public values. Despite its strong motivating rationale, implementing a One Health approach in an integrated and considered manner can be challenging, especially in the face of a perceived crisis. The effective control and prevention of EIDs therefore requires: (i) social science research to improve understanding of how EID threats and responses play out; (ii) the development of an analytic framework that catalogues case experiences with EIDs, reflects their dynamic nature and promotes inter-sectoral collaboration and knowledge synthesis; (iii) genuine public engagement processes that promote transparency, education and capture people’s preferences; (iv) a set of practical principles and values that integrate ethics into decision-making procedures, against which policies and public health responses can be assessed; (v) integration of the analytic framework and the statement of principles and values outlined above; and (vi) a focus on genuine reform rather than rhetoric.

3 November 2014 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
SHSimon Z. He
Simon Z. He
SBSamantha Busfield
Samantha Busfield
DRDavid S. Ritchie
David S. Ritchie
MHMark S. Hertzberg
Mark S. Hertzberg
SDSimon Durrant
Simon Durrant
ARAndrew W. Roberts
Andrew W. Roberts
Acute myeloid leukemia (AML) blasts express high levels of interlekin-3 (IL-3) receptor-α (CD123). CSL360 is a recombinant, chimeric immunoglobulin G1 (IgG1), anti-CD123 monoclonal antibody (MoAb) that neutralizes IL-3 and demonstrates anti-leukemic activity in vitro. This phase 1 study assessed safety, pharmacokinetics and bioactivity of weekly intravenous CSL360 for 12 weeks in 40 patients with advanced AML across five dose levels (0.1-10.0 mg/kg). Other than mild infusion reactions, CSL360 was well tolerated. The maximal tolerated dose was not reached. The half-life was 4.9 days, and the area under the curve (AUC) and maximum concentration (Cmax) increased proportionally with dose. Doses ≥ 3.0 mg/kg resulted in complete saturation and down-regulation of CD123 and abolition of ex vivo proliferative responsiveness to IL-3, indicating adequate blockade of IL-3 signaling. Two patients responded, with one remaining in complete remission after 17 doses. CSL360 bound CD123 specifically, but did not induce anti-leukemic activity in most patients. While safe, MoAb blockade of CD123 function is insufficient as a therapeutic strategy.

11 April 1998 in BMJ
Verified
Journal Article
Closed access
PDF file
IKIan Kerridge
Ian Kerridge
MLMichael Lowe
Michael Lowe
DHDavid Henry
David Henry
Evidence based medicine is founded upon an ideal—that decisions about the care of individual patients should involve the “conscientious, explicit and judicious use of current best evidence.”1 Several publications are dedicated to evidence based medicine, and, at an international level, the Cochrane Collaboration has been formed to gather, analyse, and disseminate evidence derived from published research.2 Several practical approaches to evidence based medicine in clinical decision making have also been described. 3 4 Evidence based medicine, it is claimed, leads to improvements in clinicians' knowledge, reading habits, and computer literacy; provides a framework for teaching; enables junior team members to contribute to decisions; and allows better communication with patients and more effective use of resources.5 From an ethical perspective, the strongest arguments in support of evidence based medicine are that it allows the best evaluated methods of health care (and useless or harmful methods) to be identified and enables patients and doctors to make better informed decisions. 5 6 However, the presence of reliable evidence does not ensure that better decisions will be made. Claims that evidence based medicine offers an improved method of decision making are difficult to evaluate because current practice is so poorly defined. Medical decision making draws upon a broad spectrum of knowledge—including scientific evidence, personal experience, personal biases and values, economic and political considerations, and philosophical principles (such as concern for justice). It is not always clear how practitioners integrate these factors into a final decision, but it seems unlikely that medicine can ever be entirely free of value judgments. #### Summary points Evidence based medicine is based on a strong ethical and clinical ideal—that it allows the best evaluated methods of health care to be identified and enables patients and doctors to make better informed decisions Evidence based medicine is unable to resolve competing …

1 March 2011 in American Journal of Public Health
Verified
Journal Article
Closed access
SCStacy M. Carter
Stacy M. Carter
LRLucie Rychetnik
Lucie Rychetnik
BLBeverley Lloyd
Beverley Lloyd
IKIan H. Kerridge
Ian H. Kerridge
LBLouise Baur
Louise Baur
AZAvigdor Zask
Avigdor Zask
We propose a new approach to guide health promotion practice. Health promotion should draw on 2 related systems of reasoning: an evidential system and an ethical system. Further, there are concepts, values, and procedures inherent in both health promotion evidence and ethics, and these should be made explicit. We illustrate our approach with the exemplar of intervention in weight, and use a specific mass-media campaign to show the real-world dangers of intervening with insufficient attention to ethics and evidence. Both researchers and health promotion practitioners should work to build the capacities required for evidential and ethical deliberation in the health promotion profession.